Thermo Fisher Study Compares Gene Therapy Production
Researchers analyzed three rAAV manufacturing methods to determine their impact on production costs and patient access.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Should manufacturers prioritize lower production costs to make expensive gene therapies more accessible to patients?
Researchers at Thermo Fisher Scientific released a study comparing the economic efficiency of three rAAV manufacturing platforms. The findings reveal that selecting the right production method is crucial for balancing gene therapy costs and availability.
Why it matters
Viral vector production costs are a primary driver of high gene therapy prices. By integrating quantitative cost modeling into early development, researchers aim to improve the economic sustainability and accessibility of these treatments.
The study examined three distinct rAAV manufacturing methods, identifying baculovirus infection as the most cost-efficient on a per-batch basis. Conversely, transient transfection emerged as the lowest-cost platform when normalized to vector titer.
The players
Thermo Fisher Scientific
This American supplier of scientific instrumentation and software is a major entity in the life sciences sector that provides analytical tools for pharmaceutical development.
The details
The analysis indicates that cost structures vary significantly by platform: transient transfection expenses are driven by plasmids and reagents, while PCL perfusion relies on media and single-use hardware. Baculovirus-based costs are largely influenced by downstream processing and affinity capture operations.
Timeline
The study findings were published on October 21, 2026.
The Tech Race
This research represents a shift toward data-driven manufacturing in the biotechnology sector, moving away from legacy trial-and-error production approaches. It positions developers to better compete in a market increasingly focused on scalable, cost-effective gene therapy delivery.
By optimizing manufacturing efficiency, this study could eventually lead to lower price points for critical gene therapies. Patients may see improved availability as developers align production platforms with target population needs.
The takeaway
Developers must carefully evaluate their specific indication requirements and patient population size when selecting a production platform. Choosing the most efficient method at the outset is essential to ensure long-term sustainability for high-cost medical treatments.
Further reading
For more information on the evolving production landscape, visit the Biotech section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Should manufacturers prioritize lower production costs to make expensive gene therapies more accessible to patients?
